Antares Pharma, Inc. (NASDAQ:ATRS) is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, ATRS to report 3Q20 income of $ 0.02 per share.
For the full year, analysts anticipate top line of $ 140.95 million, while looking forward to income of $ 0.06 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 135.00 million ~ $ 155.00 million
Click Here For More Historical Outlooks Of Antares Pharma, Inc.
Previous Quarter Performance
Antares Pharma, Inc. disclosed income for the second quarter of $ 0.01 per share, from the revenue of $ 32.38 million. The quarterly revenues expanded 13.89 percent compared with the same quarter last year. Street analysts expected $ 30.38 million. The top line results outshined analysts by $ 2.00 million or 6.58 percent.
Stock Performance
Shares of Antares Pharma, Inc. traded up $ 0.04 or 1.35 percent on Wednesday, reaching $ 3.01 with volume of 975.20 thousand shares. Antares Pharma, Inc. has traded high as $ 3.10 and has cracked $ 2.93 on the downward trend
The closing price of $ 3.01, representing a 85.63 % increase from the 52 week low of $ 1.60 and a 42.11 % decrease over the 52 week high of $ 5.13.
The company has a market capital of $ 499.94 million and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
Antares Pharma, Inc. will be hosting a conference call at 8:30 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.antarespharma.com
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The companys injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.
